$-2.12
(Market cap
$153,593 Mln
Revenue (TTM)
$45,134 Mln
P/E Ratio
24.7
P/B Ratio
3
Div. Yield
2.7 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$5,199 Mln
-
ROE
0.1 %
-
ROCE
10 %
-
Industry P/E
50.52
-
EV/EBITDA
15.4
-
Debt to Equity
0.6
-
Book Value
$--
-
EPS
$3.6
-
Face value
--
-
Shares outstanding
1,741,813,154
10 Years Aggregate
CFO
$63,126.00 Mln
EBITDA
$66,879.00 Mln
Net Profit
$38,861.00 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Abbott Laboratories (ABT)
| -29.4 | 4.8 | -19.5 | -34.0 | -5.9 | -4.3 | 9.0 |
|
BSE Sensex*
| -8.9 | 2.5 | 1.4 | -5.5 | 6.8 | 8.1 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Abbott Laboratories (ABT)
| 10.8 | 2.7 | 0.3 | -22.0 | 30.5 | 28.0 | 22.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Abbott Laboratories (ABT)
|
88.5 | 153,593.1 | 45,134.0 | 6,276.0 | 15.4 | 12.2 | 24.7 | 3.0 |
| 141.6 | 40,295.0 | 21,365.0 | 1,138.0 | 9.9 | 4.6 | 25.5 | 1.7 | |
| 45.0 | 70,111.4 | 20,615.0 | 3,553.0 | 19.9 | 14.5 | 19.7 | 2.8 | |
| 177.8 | 127,957.8 | 24,778.0 | 3,689.0 | 18.5 | 7.1 | 35.1 | 2.4 | |
| 86.7 | 49,006.3 | 6,303.5 | 1,092.8 | 12.7 | 10.6 | 46 | 4.8 | |
| 546.1 | 44,243.9 | 4,446.1 | 1,095.2 | 31.7 | 70.3 | 41.3 | 28.4 | |
| 402.2 | 145,582.2 | 10,582.1 | 2,979.1 | 25.0 | 17.2 | 50 | 8.3 | |
| 78.1 | 103,134.5 | 36,364.0 | 4,800.0 | 13.3 | 19.6 | 21.5 | 2.1 | |
| 301.1 | 117,170.4 | 25,270.0 | 3,337.0 | 18.7 | 15.1 | 35.3 | 5.1 | |
| 461.7 | 176,765.5 | 45,197.0 | 6,859.0 | 19.2 | 13.3 | 26.2 | 3.4 |
Shareholding Pattern
View DetailsAbout Abbott Laboratories (ABT)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and... Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois. Read more
-
Chairman of the Board, President & CEO
Mr. Robert B. Ford
-
Chairman of the Board, President & CEO
Mr. Robert B. Ford
-
Headquarters
Abbott Park, IL
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Abbott Laboratories (ABT)
What is the current share price of Abbott Laboratories (ABT) Today?
The share price of Abbott Laboratories (ABT) is $88.50 (NYSE) as of 17-Jun-2026 16:08 EDT. Abbott Laboratories (ABT) has given a return of -5.9% in the last 3 years.
What is the current PB & PE ratio of Abbott Laboratories (ABT)?
The P/E ratio of Abbott Laboratories (ABT) is 24.70 times as on 12-Jun-2026, a 51 discount to its peers’ median range of 50.52 times.
The P/B ratio of Abbott Laboratories (ABT) is 2.98 times as on 12-Jun-2026, a 12 discount to its peers’ median range of 3.37 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
33.55
|
4.20
|
|
2024
|
14.74
|
4.14
|
|
2023
|
33.62
|
4.98
|
|
2022
|
27.78
|
5.25
|
|
2021
|
35.47
|
7.01
|
What is the 52 Week High and Low of Abbott Laboratories (ABT)?
The 52-week high and low of Abbott Laboratories (ABT) are Rs 139.05 and Rs 81.97 as of 18-Jun-2026.
What is the market cap of Abbott Laboratories (ABT)?
Abbott Laboratories (ABT) has a market capitalisation of $ 153,593 Mln as on 12-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Abbott Laboratories (ABT)?
Before investing in Abbott Laboratories (ABT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.